Pluri’s Post

Check out the latest report from IMIR Market Research Pvt. Ltd. on the 𝗔𝘂𝘁𝗼𝗺𝗮𝘁𝗲𝗱 𝗔𝗻𝗱 𝗖𝗹𝗼𝘀𝗲𝗱 𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗣𝗿𝗼𝗰𝗲𝘀𝘀𝗶𝗻𝗴 𝗦𝘆𝘀𝘁𝗲𝗺𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 Outlook and Geography Forecast till 2031 Don't miss out on this opportunity to stay informed about the latest trends in the industry. Automated And Closed Cell Therapy Processing Systems Market Size, Share & Trends Analysis Report By Workflow (Separation, Expansion, Apheresis, Fill- Finish, Cryopreservation, Others), By Type (Stem Cell Therapy, Non-Stem Cell Therapy), By Scale (Pre-commercial/R&D Scale, Commercial Scale) , COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028 📚 𝐆𝐞𝐭 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 𝐝𝐢𝐬𝐜𝐨𝐮𝐧𝐭𝐞𝐝 𝐩𝐫𝐢𝐜𝐞:👇 https://lnkd.in/dqGXypG7 📚𝐓𝐨𝐩 𝐌𝐨𝐫𝐞 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐀𝐫𝐞::👇 SOTIO Biotech Southwest Research Institute SQZ Biotechnologies Stafa Cellular Therapy STEMCELL Technologies Stemedica Cell Technologies, Inc Stempeutics Research Private Limited Surface Oncology Inc. Tactiva Therapeutics Taiwan Bio Therapeutics Co., Ltd. Takara Bio USA, Inc. Takeda Pharmaceuticals (formerly Nycomed) TapImmune Inc Targazyme TC BioPharm TERUMO BCT LTD. Tessa Therapeutics Ltd Teva Pharmaceuticals Theracell Advanced Biotechnology Ltd Thermo Fisher Scientific ThermoGenesis Holdings, Inc. TIGENIX NV TILT Biotherapeutics Ltd Tmunity Therapeutics Incorporated TNK Therapeutics, Inc. TotipotentRX TRACT Therapeutics, Inc. TrakCel TransCure bioServices Triumvira Immunologics, Inc. TVAX Biomedical, Inc. Universal Cells #celltherapy #nexentury #glutax #stemcell #lucchinistemcell #lucchini #nexenturymalaysia #antiaging #biocellforte #revivalrna #nexenturyoriginal #revivalstemcell #lucchinisheepplacenta #lucchiniplacenta #revivalplantstemcell #lucchiniplacentastemcell #nexenturymurah #placentalucchinistemcell #stemcelltherapy #lucchinihexaoptimcelltherapy #revival #bioswissstemcell #stemcells #regenerativemedicine #whitening #melsmon #stemcellinjection #gs #genetherapy #lucchinihexacelltherapy

Cell Therapy Technologies Market worth $7.8 billion by 2028 Get Sample PDF Report @ https://lnkd.in/ddZsrpPi North America accounted for the largest share of the market, followed by Europe & Asia Pacific. The region's dominant position can be attributed to several key factors such as presence of leading market players and increased government investments in cell-based research. Key players in the cell therapy technologies market Thermo Fisher Scientific, Merck KGaA, Darmstadt, Germany Danaher Corporation Becton, Dickinson and Company, AL Group Lonza Sartorius AG Microsites Start A Misson Century Therapeutics, Inc CCRM GROW RESEARCH LABORATORY, NNF 3 Eyes Limited Terumo Cardiovascular Shoreline Biosciences, Inc. Marker Therapeutics, Inc. Terumo Blood and Cell Technologies JW Therapeutics 药明巨诺 MicroVention - Faith Biotech Kite Pharma Juno Therapeutics, Inc. bluebird bio Sangamo Therapeutics, Inc. Fate Therapeutics Inc. Allogene Therapeutics Adaptimmune CRISPR Therapeutics Editas Medicine #CellTherapy #MarketResearch #Biopharma #HealthcareInnovation #GlobalForecast2028

iPSC Market Leaders and their Business Models - https://lnkd.in/dkU6JngW Today, induced pluripotent stem cells (iPSCs) are being exploited for uses in drug discovery and development, toxicology screening, disease modelling, personalized medicine, cell-based therapeutics, and beyond. A fascinatingly diverse range of business models have been developed by market competitors to provide iPSC specific products, services, technologies, and therapies across the life science sector. Reprogramming kits, reagents, iPS cell lines, and specific culture media are supplied by companies specializing in iPSCs, including FUJIFILM Cellular Dynamics, Inc CDI, Ncardia, Axol Bioscience Ltd., REPROCELL, and others. Diversified research supply companies such as R&D Systems, Promega Corporation , Miltenyi Biotec, STEMCELL Technologies, Takara Bio USA, Inc., Thermo Fisher Scientific, and numerous others also provide iPSC-related research products to the scientific community. Additionally, iPSC specialists have emerged, such as iXCells Biotechnologies which provides normal and diseased iPS cell lines, iPSC-derived cells, custom iPSC services, and functional bioassay development and execution, among related products and services. Likewise, DefiniGEN, Evotec, Ncardia, Fujifilm Cellular Dynamics and Axol Bioscience are leaders in offering iPSC differentiation services. Within the world of industrial scale iPSC manufacturing, FUJIFILM CDI, TreeFrog Therapeutics, and Catalent Pharma Solutions (acquired Rheincell Therapeutics) are three companies who are leading the charge. Some of the major firms exploiting iPSC technologies for therapeutic applications include Cynata Therapeutics, iPierian Inc. (Bristol Myers Squibb), Fate Therapeutics Inc., Century Therapeutics, Inc, and BlueRock Therapeutics. In addition to these companies, dozens of others have now joined their ranks. Read more at: https://lnkd.in/dkU6JngW #ipsc #marketleaders #stemcell

iPSC Market Leaders and their Business Models - https://lnkd.in/e5WM_CSQ Today, induced pluripotent stem cells (iPSCs) are being exploited for uses in drug discovery and development, toxicology screening, disease modelling, personalized medicine, cell-based therapeutics, and beyond. A fascinatingly diverse range of business models have been developed by market competitors to provide iPSC specific products, services, technologies, and therapies across the life science sector. Reprogramming kits, reagents, iPS cell lines, and specific culture media are supplied by companies specializing in iPSCs, including FUJIFILM Cellular Dynamics, Inc CDI, Ncardia, Axol Bioscience Ltd., REPROCELL, and others. Diversified research supply companies such as R&D Systems, Promega Corporation , Miltenyi Biotec, STEMCELL Technologies, Takara Bio USA, Inc., Thermo Fisher Scientific, and numerous others also provide iPSC-related research products to the scientific community. Additionally, iPSC specialists have emerged, such as iXCells Biotechnologies which provides normal and diseased iPS cell lines, iPSC-derived cells, custom iPSC services, and functional bioassay development and execution, among related products and services. Likewise, DefiniGEN, Evotec, Ncardia, Fujifilm Cellular Dynamics and Axol Bioscience are leaders in offering iPSC differentiation services. Within the world of industrial scale iPSC manufacturing, FUJIFILM CDI, TreeFrog Therapeutics, and Catalent Pharma Solutions (acquired Rheincell Therapeutics) are three companies who are leading the charge. Some of the major firms exploiting iPSC technologies for therapeutic applications include Cynata Therapeutics, iPierian Inc. (Bristol Myers Squibb), Fate Therapeutics Inc., Century Therapeutics, Inc, and BlueRock Therapeutics. In addition to these companies, dozens of others have now joined their ranks. Read more at: https://lnkd.in/e5WM_CSQ #ipsc #marketleaders #stemcell

Great article from David Wild, pharma and biotech reporter, InVivo, the Citeline Commercial publication, covering the latest advances in the #exosome field. It results from an interview with Hugues Wallemacq, CEO, EXO Biologics , where he covers EXO Biologics' launch of the 1st EU clinical trial of an exosome #therapeutic, a Phase I/II study in preterm newborns with #bronchopulmonary #dysplasia, a deadly respiratory disease with no treatment, as well as the launch of the subsidiary ExoXpert, the 1st global exosome #CDMO #manufacturer. Will be really interesting to see EXO Biologics' next steps in advancing the exosome field. https://lnkd.in/et3Q84xJ

💉𝗖𝗔𝗥 𝗧 𝗖𝗲𝗹𝗹 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝘀 𝗯𝘆 𝗦𝗮𝗹𝗲𝘀 𝗶𝗻 𝟮𝟬𝟮𝟯 💸 🔵 The global CAR T cell therapy market size is likely to be worth USD 4.6 billion in 2024, and is projected to reach USD 25 billion by 2035, growing at a CAGR of 20% during the period 2024-2035. 🔵 CAR-T cell therapies have firmly established themselves in the pharmaceutical industry, with ongoing innovations propelling the field forward! ⭐ Here's an overview of the current landscape: 🔷 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀: 🔹 Around 1,000 clinical trials related to CAR-T cell therapies have been registered in the past eight years, with nearly 60% of these trials actively recruiting patients. 🔹 Nearly 300 therapies are targeting oncological disorders in the early stages of development. 🔷 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗣𝗿𝗲𝘀𝗲𝗻𝗰𝗲: 🔹 More than 190 CAR-T cell therapy companies are actively working on potential treatments for oncological, non-oncological, and other disorders. 🔷 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻𝘀: 🔹 There are over 260 partnerships and collaborations between industry and academic stakeholders aimed at expediting the development of pipeline candidates. 🔷 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁𝘀: 🔹 Capital investments totaling more than USD 32 billion have been made by both private and public sector investors in recent years. 🔷 𝗜𝗻𝘁𝗲𝗹𝗹𝗲𝗰𝘁𝘂𝗮𝗹 𝗣𝗿𝗼𝗽𝗲𝗿𝘁𝘆: 🔹 Over 10,000 patents have been filed or granted related to CAR-T cell therapies. 🔷 𝗔𝗽𝗽𝗿𝗼𝘃𝗲𝗱 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝘀 1️⃣ #Yescarta (anti-CD19) ⏩ Kite Pharma 2️⃣ #Abecma (anti-BCMA) ⏩ Bristol Myers Squibb 3️⃣ #Kymriah (anti-CD19) ⏩ Novartis 4️⃣ #Carvykti (anti-BCMA) ⏩ Janssen Inc. 5️⃣ #Tecartus (anti-CD19) ⏩ Kite Pharma 6️⃣ #Breyanzi (anti-CD19) ⏩ Bristol Myers Squibb 📚 Source: Companies' Annual Reports, Roots Analysis Report #cartcelltherapy #celltherapy #genetherapy #bigpharma #biologicals #pharmaceuticalindustry #biotechnology #marketresearch #pharma #biopharma #annualsales #topseller

The global CAR T cell therapy market size is likely to be worth USD 4.6 billion in 2024, and is projected to reach USD 25 billion by 2035, growing at a CAGR of 20% during the period 2024-2035. #globalmarket #growthstrategy #2024healthtrends

Balancing Value and Access: The Rationale Behind Lenmeldy™’s $4.25 Million Tag Orchard Therapeutics, acquired by Kyowa Kirin, has announced its US commercial launch plans for Lenmeldy, the first FDA-approved therapy for early-onset metachromatic leukodystrophy (MLD). MLD is a rare and fatal neurometabolic disorder that affects 1 in 100,000 live births in the US. Lenmeldy aims to treat MLD by introducing functional copies of the ARSA gene into a patient's stem cells. Orchard Therapeutics is establishing specialized treatment centers across the US and offering patient services to make the therapy accessible. The wholesale acquisition cost of Lenmeldy is set at $4.25 million. Orchard Therapeutics is also working on outcomes- and value-based agreements with insurers to ensure access to the therapy. The company supports efforts to expand newborn screening for MLD. The launch of Lenmeldy represents a significant advancement in MLD treatment. For more details please click the link! https://lnkd.in/dHnQhZ8p #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

𝗖𝗵𝗶𝘁𝗼𝘀𝗮𝗻 𝗡𝗮𝗻𝗼𝗽𝗮𝗿𝘁𝗶𝗰𝗹𝗲𝘀 𝗳𝗼𝗿 𝗜𝗻𝘁𝗿𝗮𝗻𝗮𝘀𝗮𝗹 𝗗𝗿𝘂𝗴 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 This manuscript explores the use of nanostructured chitosan for intranasal drug delivery, targeting improved therapeutic outcomes in neurodegenerative diseases, psychiatric care, pain management, vaccination, and diabetes treatment. Chitosan nanoparticles are shown to enhance brain delivery, improve bioavailability, and minimize systemic side effects by facilitating drug transport across the blood–brain barrier. Despite substantial advancements in targeted delivery and vaccine efficacy, challenges remain in scalability, regulatory approval, and transitioning from preclinical studies to clinical applications. Read more in the article. #pharmaceutical #chitosan #nasal #drugdelivery

Just read a new Nature Biotechnology article (published March 8). Congratulations to the team of Insilico Medicine (Alex Zhavoronkov) to this major milestone (not only for Insilico, but for the entire industry). Notwithstanding the published principles of virtually discovering a new TNIK inhibitor for the treatment of fibrosis, this article highlights which role AI can have in a future pharma R&D. Enjoy reading: https://lnkd.in/dk7S5dVZ #pharma #insilsico #drug #drugdiscovery #drugdevelopment #AI #artificialintelligenes